Current trends in the management of oligometastatic prostate cancer

In what one of the authors has described as “a somewhat critical and light-hearted look at our current enthusiasm for aggressive approaches to oligometastatic prostate cancer”, an article currently in press asks some serious questions about the use of metastasis-directed therapy or MTD in the management of such patients. … READ MORE …

Treating metastatic prostate cancer in very elderly men: a review

A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in Aging. … READ MORE …

Incidence, outcomes, ethnicity, and distant, de novo, metastatic prostate cancer

Diagnosis of men with distant, metastatic prostate cancer at first presentation (distant, “de novo”, metastatic prostate cancer) is a lot less common today than it was 30 or 40 years ago, but it does still happen on a regular basis. … READ MORE …

Results of Prostvac PROSPECT trial scheduled for later in 2017

According to Barvarian Nordic, the key results of the Phase III clinical trial of the immunologic agent Prostvac (rilimogene galvacirepvec/rilimogene glafolivec, or “rilimogene”) in treatment of metastatic, castration-resistant prostate cancer (mCRPC) are now expected in the second half of 2017. … READ MORE …

No sign of evident clinical benefit in the Phase IV PLATO trial

According to a recent media release, there was no significant benefit for the investigational combination of enzalutamide (Xtandi) + abiraterone acetate (Zytiga) + prednisone in treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (cnmCRPC). … READ MORE …

Lu-177-PSMA-617: another update

Because there is great interest in systemic therapies for metastatic prostate cancer, we want to provide readers with the latest news about the 177Lu PSMA-617 trials in Germany. … READ MORE …

Data from the Phase III clinical trial of ipilimumab

Just over 3 years ago, Bristol-Myers Squibb announced that treatment with ipilimumab (Yervoy) had failed to show a survival benefit in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). For readers who may be interested, the data from this trial have finally been reported by Beer et al. in the Journal of Clinical Oncology.